This study is for participants who previously completed a KarXT study and aims to assess the long-term safety and tolerability of KarXT in individuals with psychosis associated with Alzheimer’s disease.
Eligibility:
• Ages 55–90
• Must have completed study KAR-031 or KAR-032
• Must have a caregiver or study partner who can attend all visits